Displaying drugs 10126 - 10150 of 12433 in total
Inbakicept
Inbakicept is a dimeric human IL-15 receptor α (IL-15Rα) sushi domain/human IgG1 Fc fusion protein. It is one of the active ingredients in Anktiva, a combination product also containing nogapendekin alfa, where a single inbakicept is complexed with two nogapendekin alfa components. This combination product was approved by the FDA...
Investigational
Matched Description: … It is one of the active ingredients in Anktiva, a combination product also containing [nogapendekin alfa ... [L50627] Non-muscle invasive bladder cancer (NMIBC), which accounts for 75% of all bladder tumours, is ... commonly treated with transurethral resection of the bladder tumour and Bacillus Calmette-Guérin (BCG …
Trapidil
Trapidil, a platelet-derived growth factor antagonist, was originally developed as a vasodilator and anti-platelet agent and has been used to treat patients with ischemic coronary heart, liver, and kidney disease.
Experimental
Molnupiravir
Molnupiravir (EIDD-2801, MK-4482) is the isopropylester prodrug of N4-hydroxycytidine.[A193014,A193026] With improved oral bioavailability in non-human primates, it is hydrolyzed in vivo, and distributes into tissues where it becomes the active 5’-triphosphate form. The active drug incorporates into the genome of RNA viruses, leading to an accumulation of mutations known as...
Investigational
Matched Description: … [A193026] The active drug incorporates into the genome of RNA viruses, leading to an accumulation of ... Molnupiravir (EIDD-2801, MK-4482) is the isopropylester prodrug of [N4-hydroxycytidine]. ... [A193029] Recent studies have shown molnupiravir inhibits replication of human and bat coronaviruses, …
XL765
XL765 is an orally available small molecule that has been shown in preclinical studies to selectively inhibit the activity of phosphoinositide-3 kinase (PI3K) and mammalian target of rapamycin (mTOR). It is being developed by Exelixis, Inc.
Investigational
Matched Description: … phosphoinositide-3 kinase (PI3K) and mammalian target of rapamycin (mTOR). ... available small molecule that has been shown in preclinical studies to selectively inhibit the activity of …
Ranpirnase
Ranpirnase is a ribonuclease enzyme found in Rana pipiens oocytes. It is being studied in the treatment of cancer. It is manufactured by Alfacell Corporation. It is the first ribonuclease to enter cancer clinical trials.
Investigational
Matched Description: … It is being studied in the treatment of cancer. It is manufactured by Alfacell Corporation. …
AP5346
AP5346 is designed to target a diaminocyclohexane platinum (Pt) moiety to tumors through pH-sensitive linkage to a 25 kDa hydroxypropylmethacrylamide polymer. It is being pursued by Access Pharmaceuticals, Inc.
Investigational
XL019
XL019 is a selective inhibitor of the cytoplasmic tyrosine kinase JAK2. An IND for XL019 was filed by Exelixis in May 2007.
Investigational
Matched Description: … XL019 is a selective inhibitor of the cytoplasmic tyrosine kinase JAK2. …
Tesmilifene
Tesmilifene is a novel potentiator of chemotherapy which, when added to doxorubicin, achieved an unexpected and very large survival advantage over doxorubicin alone in a randomized trial in advanced breast cancer.
Investigational
Matched Description: … Tesmilifene is a novel potentiator of chemotherapy which, when added to doxorubicin, achieved an unexpected …
CG7870
CG7870 is an oncolytic virus therapy for prostate cancer. It is a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer.
Investigational
Matched Description: … a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of …
1D09C3
1D09C3, a monoclonal antibody against lymphoid cancers, is an anti-MHC (major histocompatibility complex) class II monoclonal antibody. The antibody was isolated in collaboration with MorphoSys from its HuCAL(R) library of human antibodies. 1D09C3 binds to certain cell surface receptors, selectively killing activated, proliferating MHC class II-positive tumor cells, which include...
Investigational
Matched Description: … The antibody was isolated in collaboration with MorphoSys from its HuCAL(R) library of human antibodies …
ZYC300
ZYC300 is a plasmid DNA of CYP1B1 encapsulated in biodegradable poly-DL-lactide-coglycolide microparticles. It is designed as a vaccine, intended to increase immune system sensitivity to CYP1B1, an enzyme highly prevalent in tumor cells.
Investigational
Matched Description: … ZYC300 is a plasmid DNA of CYP1B1 encapsulated in biodegradable poly-DL-lactide-coglycolide microparticles …
Garetosmab
Fibrodysplasia ossificans progressiva (FOP) is a rare autosomal dominant disorder of episodic, progressive heterotropic ossification. FOP is characterized by episodic inflammatory episodes, which may be precipitated by trauma, including immunizations and minor tissue damage, which usually result in ossification of the lesion. Patients experience abnormal cartilage formation, growth plate dysplasia,...
Investigational
Matched Description: … Fibrodysplasia ossificans progressiva (FOP) is a rare autosomal dominant disorder of episodic, progressive ... [A242297, A242307] The discovery of an activating mutation in the ACVR1 receptor that renders it responsive ... precipitated by trauma, including immunizations and minor tissue damage, which usually result in ossification of …
Ephedra sinica root
Ephedra is an alkaloid chemical compound traditionally obtained from the plant Ephedra sinica. The sale of ephedra-containing supplements intended to increase muscle weight or promote weight loss was banned in the United States in 2004 due to the risk for adverse effects and a lack of evidence for clinical effectiveness....
Nutraceutical
Matched Description: … The sale of ephedra-containing supplements intended to increase muscle weight or promote weight loss ... was banned in the United States in 2004 due to the risk for adverse effects and a lack of evidence for …
NV1020
NV1020, a genetically engineered herpes simplex virus, is a novel anticancer therapeutic.
Investigational
LErafAON
NeoPharm is developing liposome-encapsulated, c-Raf antisense oligodeoxynucleotides (LErafAON) for the potential treatment of various solid tumors, including those that have become resistant to radiation or chemotherapy. Phase I/II trials commenced in March 2001 and were ongoing as of June 2003.
Investigational
Matched Description: … Phase I/II trials commenced in March 2001 and were ongoing as of June 2003. ... liposome-encapsulated, c-Raf antisense oligodeoxynucleotides (LErafAON) for the potential treatment of …
SP1049C
SP1049C is a novel anthracycline chemotherapeutic agent containing doxorubicin and two nonionic pluronic block copolymers. It is designed to overcome drug resistance in a number of cancers. It has successfully completed Phase 1 trials. Phase 2 results are currently under final review. Preliminary data, in its first clinically tested indication,...
Investigational
Matched Description: … [A260416] It is designed to overcome drug resistance in a number of cancers. ... clinically tested indication, shows that SP1049C is active in Stage IV non-resectable adenocarcinoma of …
IGN311
IGN311 is a humanized monoclonal antibody (mab) against the Lewis Y carbohydrate antigen, a blood-group-related oligosaccharide.
Investigational
SR 121463
SR 121463 is a nonpeptide aquaretic compound with potent selective antagonism of the vasopressin V2 (V1b) receptor subtype. It is a candidate for control of hyponatremia and in the treatment of syndrome of inappropriate secretion of anti-diuretic hormone (SIADH).
Investigational
Matched Description: … It is a candidate for control of hyponatremia and in the treatment of syndrome of inappropriate secretion ... of anti-diuretic hormone (SIADH). ... SR 121463 is a nonpeptide aquaretic compound with potent selective antagonism of the vasopressin V2 ( …
M40403
M40403 is a low molecular weight, synthetic manganese containing superoxide dismutase mimetic (SODm) that selectively removes superoxide anion.
Investigational
Ty800
Ty800 is a vaccine designed to offer rapid, oral, single-dose protection against Salmonella typhi, the cause of typhoid fever. The Ty800 vaccine was developed using genetic techniques to delete specific genes known to be essential to the virulence of S. typhi. It is being developed by AVANT Immunotherapeutics, Inc.
Investigational
Matched Description: … vaccine designed to offer rapid, oral, single-dose protection against Salmonella typhi, the cause of ... developed using genetic techniques to delete specific genes known to be essential to the virulence of …
AC3056
AC3056 is a non-peptide antioxidant that acts as an inhibitor of vascular cell adhesion molecule expression originally developed by Aventis Pharmaceuticals. It as since been acquired by Amylin Pharmaceuticals and has completed phase I trials.
Investigational
Matched Description: … AC3056 is a non-peptide antioxidant that acts as an inhibitor of vascular cell adhesion molecule expression …
Atipamezole
Atipamezole is a synthetic α2 adrenoceptor antagonistused to reverse the sedative and analgesic effects of dexmedetomidine and medetomidine in dogs. It has also been undergone research as a potential anti-Parkinsonian drug for humans.
Investigational
Vet approved
Matched Description: … Atipamezole is a synthetic α2 adrenoceptor antagonistused to reverse the sedative and analgesic effects of …
Fencamfamin
Fencamfamin (Glucoenergan, Reactivan) is a stimulant which was developed in the 1960s as an appetite suppressant, but was later withdrawn for this application due to problems with dependence and abuse. It is around half the potency of dexamphetamine, and is prescribed at a dose of 10-60mg, although abusers of the...
Experimental
Illicit
Withdrawn
Matched Description: … It is around half the potency of [dexamphetamine], and is prescribed at a dose of 10-60mg, although abusers ... of the drug tend to rapidly develop tolerance and escalate their dose. ... Fencamfamin is used for treating depressive day-time fatigue, lack of concentration and lethargy. …
Vilobelimab
Vilobelimab is a chimeric monoclonal immunoglobulin G4 (IgG4) antibody that binds to the soluble form of human C5a with high affinity. It consists of mouse anti-human complement factor 5a (C5a) monoclonal binding sites (variable regions of heavy and light chain regions) and human gamma 4 heavy chain and light kappa...
Investigational
Matched Description: … Vilobelimab is a chimeric monoclonal immunoglobulin G4 (IgG4) antibody that binds to the soluble form of ... It consists of mouse anti-human complement factor 5a (C5a) monoclonal binding sites (variable regions ... of heavy and light chain regions) and human gamma 4 heavy chain and light kappa chain constant regions …
Displaying drugs 10126 - 10150 of 12433 in total